Prenetics Global Limited (PRE)
| Market Cap | 306.40M +47.5% |
| Revenue (ttm) | 154.59M +171.0% |
| Net Income | -47.00M |
| EPS | -2.93 |
| Shares Out | 16.94M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,889 |
| Open | 18.09 |
| Previous Close | 17.55 |
| Day's Range | 18.09 - 18.09 |
| 52-Week Range | 11.37 - 27.24 |
| Beta | 0.40 |
| Analysts | Strong Buy |
| Price Target | 38.44 (+112.49%) |
| Earnings Date | Nov 18, 2026 |
About PRE
Prenetics Global Limited operates as a consumer health sciences company in the United States and Hong Kong. The company focuses on advancing human health and longevity through science-backed products under the IM8 brand. It also operates a consumer genetic testing brand in CircleDNA leveraging sequencing technology to deliver personalized reports across various categories. The company was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
Financial Performance
In 2025, Prenetics Global's revenue was $92.39 million, an increase of 479.76% compared to the previous year's $15.94 million. Losses were -$37.71 million, -18.56% less than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for PRE stock is "Strong Buy." The 12-month stock price target is $38.44, which is an increase of 112.49% from the latest price.
News
Care Bears And Prenetics' IM8 Announce Global Partnership
IM8 family wellness brand to launch gummy multivitamins for kids and adults in 2027, marking Care Bears' 45th anniversary NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Care Bears, part of Authentic Brands Gr...
Prenetics' IM8 and Authentic Brands Group Announce 10-Year Exclusive Global Partnership to Create Care Bears by IM8; Authentic to Become Strategic Shareholder in Prenetics
Care Bears by IM8 to launch, with great-tasting, science-backed gummy multivitamins for kids and adults in 1H 2027 Enters a global gummy supplements market projected to nearly double to ~US$47.8 billi...
Prenetics' IM8 Names Brian J. Rosin as Successor Chief Financial Officer
- Completes planned leadership transition as Prenetics revenue is almost entirely IM8 - Prenetics' finance leadership function now based in the United States - The Company will report third quarter 20...
Prenetics falls after CFO Stephen Hoi Chun tenders resignation
Prenetics (PRE) is moving lower after the company this morning disclosed that Stephen Hoi Chun Lo tendered his resignation as Chief Financial Officer, effective December 30, to pursue new opportunitie...
Maxim starts Prenetics at Buy amid consumer interest in health and wellness
As previously reported, Maxim initiated coverage of Prenetics (PRE) with a Buy rating and $41 price target The company is well-positioned to capitalize on consumers’ increasing interest in health &…
Prenetics initiated with a Buy at Maxim
Maxim analyst Tom Forte initiated coverage of Prenetics (PRE) with a Buy rating and $41 price target
Prenetics initiated with a Buy at Titan Partners
Titan Partners analyst Kyle Bauser initiated coverage of Prenetics (PRE) with a Buy rating and $52 price target Prenetics is a consumer health company focused on its premium wellness brand,…
Prenetics initiated with a Buy at Lucid Capital
Lucid Capital initiated coverage of Prenetics (PRE) with a Buy rating and $54 price target The firm says prevention, wellness, and longevity is not a fad category. The sector “will…
Prenetics Global Registration statement: Registration filing
Prenetics Global filed a registration statement on September 22, 2026, providing details about a securities offering with the SEC.
Craig-Hallum bullish on Prenetics, initiates with a Buy
As previously reported, Craig-Hallum analyst Eric Des Lauriers initiated coverage of Prenetics (PRE) with a Buy rating and $40 price target Despite becoming the quickest supplement brand to reach $100...
Prenetics initiated with a Buy at Craig-Hallum
Craig-Hallum initiated coverage of Prenetics (PRE) with a Buy rating and $40 price target
Prenetics Global Registration statement: Registration filing
Prenetics Global filed a registration statement on September 8, 2026, providing details about a securities offering with the SEC.
Prenetics initiated with a Buy at B. Riley
B. Riley initiated coverage of Prenetics (PRE) with a Buy rating and $37 price target The firm says its investment thesis is predicated upon Prenetics becoming U.S.-domiciled. The company transformed…
Prenetics' IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results
Cumulative Personal Investment by Leadership Since November 2025 Reaches Approximately $3.75 Million NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or ...
Prenetics' IM8 Announces Two-Time Golden Globe-Nominated Actress and Producer Lily Collins as IM8 Global Ambassador and Shareholder in Multi-Year Partnership
— Lily is IM8's first Global Ambassador from film and television, extending a roster built in elite sport into global entertainment and culture — Lily brings a following of more than 33 million across...
Prenetics Global Earnings Call Transcript: Q2 2026
Q2 revenue grew 29% sequentially to $46.5M, with IM8 at $45M and 65% gross margin. July marked the first positive adjusted free cash flow month, driven by strong subscriber growth and a $1B General Catalyst funding. Full-year revenue guidance was raised to $220M–$230M, with new product launches representing further upside.
Prenetics Global Slides: Q2 2026
Prenetics Global has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 18, 2026.
Prenetics Global Shareholder letter: Q2 2026
Prenetics Global has published a letter to shareholders covering Q2 2026, which was released on August 18, 2026.
Prenetics Global Earnings release: Q2 2026
Prenetics Global released its Q2 2026 earnings on August 18, 2026, summarizing the period's financial results.
Prenetics' IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220–230 Million; July Was the First Month of Positive Consolidated Adjusted Free Cash Flow and Expected to Remain Positive for Q3 and Beyond
Prenetics' IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220–230 Million; July Was the First Month of Positive Co
Prenetics, Parent of IM8, Appoints II Ranked, Caroline Levy, Veteran Wall Street Consumer Analyst as Independent Director
30+ years as one of Wall Street's top-ranked equity research consumer analysts, including leadership of U.S. consumer research at UBS Caroline will also serve on the Audit Committee, Compensation Comm...
Prenetics to Report Q2 2026 Financial Results on August 18, 2026, Live-Stream Earnings Event on Stocktwits, and Announces Upcoming Conference Participation
Prenetics to Report Q2 2026 Financial Results on August 18, 2026, Live-Stream Earnings Event on Stocktwits, and Announces Upcoming Conference Participation
Prenetics Global Registration statement: Registration filing
Prenetics Global filed a registration statement on August 7, 2026, providing details about a securities offering with the SEC.
Prenetics price target raised to $35 from $29 at Lake Street
Lake Street analyst Ryan Meyers raised the firm’s price target on Prenetics (PRE) to $35 from $29 and keeps a Buy rating on the shares. The structure of the $1B…
Prenetics price target raised to $40 from $30 at Benchmark
Benchmark raised the firm’s price target on Prenetics (PRE) to $40 from $30 and keeps a Buy rating on the shares after the company announced the closing of $1B in…